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ABSTRACT
Cyclin-dependent kinase 12 (CDK12) phosphorylates
the carboxyl-terminal domain (CTD) of RNA poly-
merase II (pol II) but its roles in transcription beyond
the expression of DNA damage response genes re-
main unclear. Here, we have used TT-seq and mNET-
seq to monitor the direct effects of rapid CDK12 in-
hibition on transcription activity and CTD phospho-
rylation in human cells. CDK12 inhibition causes a
genome-wide defect in transcription elongation and
a global reduction of CTD Ser2 and Ser5 phosphory-
lation. The elongation defect is explained by the loss
of the elongation factors LEO1 and CDC73, part of
PAF1 complex, and SPT6 from the newly-elongating
pol II. Our results indicate that CDK12 is a general ac-
tivator of pol II transcription elongation and indicate
that it targets both Ser2 and Ser5 residues of the pol
II CTD.
INTRODUCTION
The phosphorylation status of the C-terminal domain
(CTD) of RNA polymerase II (pol II) plays a major role
in expression of non-coding and protein-coding genes (1).
In humans, the CTD comprises 52 repeats of the consensus
heptapeptide Tyr1/Ser2/Pro3/Thr4/Ser5/Pro6/Ser7 and is
reversibly phosphorylated by several kinases during tran-
scription (1). CDK12 is the metazoan ortholog of the Sac-
charomyces cerevisiae CTD Ser2 kinase, Ctk1 (2,3). Knock-
down of CDK12 results in loss of CTD Ser2 phosphoryla-
tion in Drosophila, Caenorhabditis elegans and human cells
(3–10). In addition, treatment with the CDK12/CDK13
inhibitor THZ531 in Jurkat cells affects pol II CTD Ser2
phosphorylation in a concentration-dependent manner (7).
Analog-sensitive (as) kinase technology has also been
used to demonstrate rapid loss of Ser2 phosphorylation
after inhibiting the Schizosaccharomyces pombe CDK12
homologue Lsk1 (11). However, knockdown of CDK12
in HCT116 cells or inhibition of CDK12as in HeLa or
HCT116 cells does not always cause loss of Ser2P (12,13),
and detecting loss of Ser2P after CDK12 inhibition ap-
pears to depend on the anti-Ser2P antibody used (14).
In addition, CDK12 mainly phosphorylates Ser5 in vitro
(15,16).
CDK12 forms a complex with Cyclin K and is recruited
to transcription units of pol II–transcribed genes (7,17–19)
and enhancers (7). Blazek et al. have shown that depletion
of CDK12 results in reduced expression of a small subset
of genes (3.9%), enriched for genes involved in the DNA
damage response (DDR), such as BRCA1 and ATR (4).
Knockdown of Cyclin K/CDK12 complexes also causes el-
evated sensitivity to DNA damage inducing agents and ac-
cumulation of the DNA damage biomarker  -H2AX (4).
In addition, CDK12(−/−) embryos have reduced expres-
sion of genes involved in the DDR (20) and mutations that
impair CDK12 kinase activity are associated with misregu-
lation of expression of DNA repair genes and ovarian carci-
noma (21,22). Downregulation of key DDR genes has also
been observed by RNA-seq analysis following CDK12 de-
pletion (12) and by microarray analysis after treatment of
cells with THZ531 (7). In line with these findings, CDK12 is
frequently mutated in high-grade serous ovarian carcinoma
(HGSOC) (23). Interestingly, small molecule inhibitors of
CDK12 also affect translation (24).
Pol II ChIP-seq and transient transcriptome sequencing
(TT-seq) analyses suggest that elongation of transcription
of genes sensitive to THZ531 is defective (7,25). In addi-
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tion, it has been recently shown in mES cells, human tu-
mours andmouse and human cell lines that downregulation
of DDR genes following depletion of CDK12 or inhibition
of CDK12/CDK13 results from the activation of intronic
poly(A) sites, leading to the production of prematurely ter-
minated gene products (10,25). However, the primary effect
of selective inhibition of CDK12 activity on transcription
remained unclear.
To better understand the function of the kinase activity
of CDK12 in transcription, we have used CRISPR/Cas9
gene engineering to mutate the endogenous CDK12 gene
in HEK293 cells to produce an analog-sensitive CDK12
(CDK12as) that can be selectively inhibited by bulky ATP
analogs (26). We have combined the use of this CDK12as
cell line with two complementary functional genomics
methods: TT-seq (27) and native elongating transcript se-
quencing for mammalian cells (mNET-seq) (28,29). TT-seq
combines 4sU-metabolic labeling with RNA fragmentation
to monitor synthesis of newly transcribed RNAs genome-
wide. mNET-seq isolates and sequences the RNA in the
active site of immunoprecipitated pol II to provide single-
nucleotide resolution of pol II occupancy and CTD modi-
fication status.
We find that short-term inhibition of CDK12 causes a
global decrease of pol II elongation velocity as measured
by TT-seq and loss of phosphorylation of Ser2 and Ser5
of the pol II CTD as measured by mNET-seq and west-
ern blot. Elongation of transcription of the vast majority of
pol II-transcribed genes is affected. CDK12 inhibition also
causes the loss of key elongation factors from pol II tran-
scription units, identifying CDK12 as a global regulator of
pol II CTD Ser2 and Ser5 phosphorylation and transcrip-
tion elongation in human cells.
MATERIALS AND METHODS
Cell culture
HEK293 cells were obtained from ATCC (ATCC® CRL-
1573™). HEK293 parental cells and CDK12as HEK293
cells were grown in DMEM medium supplemented with
10% foetal calf serum, 100U/ml penicillin, 100g/ml strep-
tomycin, 2 mM L-glutamine at 37◦C and 5%CO2. HEK293
cells were treated with 7.5 M 1-NM-PP1 (Cayman Chem-
ical Company) for 15 and 30 min. As a negative con-
trol, HEK293 cells were treated with DMSO (the resuspen-
sion vehicle for NM). Cells were routinely checked to be
free of mycoplasma contamination using Plasmo Test My-
coplasma Detection Kit (InvivoGen, rep-pt1).
Analog sensitive cell line creation
Guide RNAs were computationally designed.
Guide RNA 1: GGTCCATATACTCAAATACAA
Guide RNA 2: GTATATGGACCATGACTTAAT
The modified CDK12 genomic sequence (RefSeq Acces-
sion NM 016507) (500 bp either site of the mutation) was
cloned into pcDNA3 and used as the repair template for
genome editing. The repair template contains a TTT to
GGT mutation. The guide (g)RNAs inserts were cloned
into the pX462 vector (obtained from Addgene). HEK293
cells were transfected with the gRNA vectors and correc-
tion template using Lipofectamine 2000 (Life Technolo-
gies) following the manufacturer instructions. Single clones
were isolated by low density plating after Puromycin and
Neomycin selection. Genomic DNA from each clone was
analysed using PCR and Sanger sequencing.
gDNA preparation
Cells were incubated in 180 l ChIP lysis buffer for 10
min and sonicated for 3 min (30 s on/30 s off) using a
Q800R2 sonicator (QSONICA). 20 l ammonium acetate
was added (final conc. 400 mM) and samples were mixed
with 200 l phenol chloroform by vortexing. The sam-
ples were centrifuged (13 000 g, 5 min, 25◦C) and the up-
per phase was transferred to a new tube. Genomic DNA
was precipitated in 70% ethanol, pelleted by centrifuga-
tion (13 000 g, 5 min, 25◦C) and dissolved in nuclease free
water. A CDK12 fragment was PCR amplified using the
following primers: Forward 5′ CCAGCCATATGGGTGG
CAGAGTGAGAGTCT 3′; Reverse 5′ CCAGCGCGGC
CGCGCAGAAAAGGCCAATCA 3′. DNA was purified
using a QIAquick PCR purification kit (Qiagen) and se-
quenced by the SourceBioscience Sanger Sequencing Ser-
vice, Oxford.
RNA preparation
RNA was extracted from HEK293 cells using TRIzol
(Invitrogen) according to the manufacturer’s instructions.
Reverse-transcription (RT) was performed with 1 g of
RNA using random hexamers with the SuperScript III kit
(Invitrogen) according to the manufacturer’s instructions.
Sequencing was performed on a cDNA PCR fragment gen-
erated with Forward primer: CGCTGTGTGGACAAGT
TTGA and Reverse primer: GCTGGTGTGTAACGTT
CCTC). Sequencing primer used: GCTTCCCAATCACA
GCCATT.
Cell proliferation analysis
Cells were seeded at 500/well in 95l in 96-well microplates
(Greiner, 655090) and measured every 12 or 24 h by adding
alamarBlue HS (Invitrogen) (1/20) and reading in a fluo-
rimeter after 1 hour’s incubation, according to the manu-
facturer’s instructions.NM-PP1 orDMSOwas added to the
cells as noted on the figure. Continuous xCelligence analysis
was carried out in 96-well E-Plates (H003957) after seeding
the cells at 500/well and NMorDMSOwas added as noted
on the figure, 36 hours after seeding.
Chromatin immunoprecipitation (ChIP)
ChIP analysis were performed as previously (30) using
antibodies against control IgG (sc-2027, Santa Cruz), Pol
II (MABI0601, MBL International), Ser2P (MABI0602,
MBL International), Ser2P (ab5095, Abcam), Ser5P
(MABI0603, MBL International), Ser5P (ab5131, Abcam),
CPSF73 (A301-091A, Bethyl Laboratories), LEO1 (A300-
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Laboratories), SPT6 (15616S, Cell Signaling Technology).
ChIP samples were analysed by real-time qPCR using
QuantiTect SYBR Green PCR kit (Qiagen) and Rotor-
Gene RG-3000 (Corbett Research). Signals are presented
as percentage of Input after removing the background
signal from the IP with the IgG antibody. The sequence of
primers used for qRT-PCR is given in Table 1.
ChIP-seq of pol II in HEK293 (one replicate) or
CDK12as (biological duplicates) cells treated with DMSO
or 7.5 M 1-NM-PP1 was performed with the antibody
sc-899 X (Santa Cruz Biotechnology). ChIP-seq of Ser2P
(ab5095, Abcam), Ser5P (ab5131, Abcam), CPSF73 (A301–
091A, Bethyl Laboratories), LEO1 (A300-175A, Bethyl
Laboratories), and SPT6 (15616S, Cell Signaling Technol-
ogy) were performed in biological duplicates. Preparation of
ChIP-seq library and ChIP sequencing was prepared with
the NEBNext Ultra II DNA Library Prep Kit for Illumina
(NEB), according to themanufacturer’s instructions or con-
ducted by the high throughput genomics team of the Well-
come Trust Centre for Human Genetics (WTCHG), Ox-
ford.
Co-immunoprecipitation
For each sample: 100 l of Dynabeads M-280 Sheep anti-
mouse IgG (Thermo Fisher) were pre-blocked overnight at
4◦C on a wheel in 1 ml of PBS supplemented with 0.5%
BSA. The next day, the beads were washed three times in
IP buffer (25 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.5%
NP-40, 10% Glycerol, 2.5 mM MgCl2), before being incu-
bated for 2 hours at 4◦C on a wheel in 600 l of IP buffer
supplemented with 5 g of antibody and protease inhibitor
cocktail (cOmplete™, EDTA-free Protease Inhibitor Cock-
tail, Sigma-Aldrich). In the meantime, a 70–80% confluent
15 cm dish of CDK12as cells was washed twice with ice-cold
PBS before being scrapped with ice-cold PBS supplemented
with protease inhibitor cocktail. The cells were pelleted at
500 g for 15min at 4◦C.The pellets were re-suspended in 800
l of Lysis buffer (50 mMTris–HCl pH 8.0, 150 mMNaCl,
1%NP-40, 10% glycerol, 2.5 mMMgCl2, protease inhibitor
cocktail, PhosSTOP (Sigma-Aldrich), 1× PMSF (Sigma-
Aldrich), and 25–29 units of Benzonase (MerckMillipore))
and incubated at 4◦Con awheel for 30min. After centrifug-
ing for 15 min at 13 000 g at 4◦C, 800 l of Dilution buffer
(150 mM NaCl, 10% glycerol, 2.5 mMMgCl2, protease in-
hibitor cocktail, PhosSTOP, and 1× PMSF) was added to
the supernatant
The beads conjugated with antibodies were washed three
times with IP buffer supplemented with protease inhibitor
cocktail, then the beads and 1mgof proteinswere incubated
at 4◦C on a wheel for 2 h. The beads were then washed three
times with IP buffer containing 150 or 300 mM NaCl and
supplemented with protease inhibitor cocktail and three
times with IP buffer without NP-40, containing 150 or 300
mMNaCl, and supplemented with protease inhibitor cock-
tail. Proteins were eluted in 40 l of 1× LDS plus 100 mM
DTT for 10 min at 70◦C. Western blots were performed
with NuPAGENovex 3–8% Tris-Acetate Protein Gels (Life
Technologies).
The following antibody was used for immunoprecipita-
tion: total pol II (MABI0601, MBL International).
Western blot
Western blot analysis was performed on chromatin and nu-
cleoplasm extracts as previously described (29) until purifi-
cation of the chromatin fraction. The chromatin pellet was
digested in 100 l of nuclease-free water supplemented with
1l of Benzonase (25–29 units,MerckMillipore) for 10min
at 37◦C in a thermomixer (1400 rpm). 10 g of proteins
were boiled in 1× LDS plus 100 mM DTT. Western blots
were performed with NuPAGENovex 4–12% Bis–Tris Pro-
tein Gels (Life Technologies).
For whole cell extract, cells were washed in ice-cold PBS
twice, collected in ice-cold PBS by 3000 rpm centrifuge for
5 min at 4◦C. The pellets were re-suspended in RIPA buffer,
kept on ice for 30 min with a vortexing step every 10 min.
After centrifugation at 14 000 g for 15min at 4◦C, the super-
natants were kept and quantifiedwith the Bradfordmethod.
20g of proteins were boiled in 1×LDS plus 100mMDTT.
Western blots were performed withNuPAGENovex 4–12%
Bis–Tris Protein Gels (Life Technologies).
The following antibodies were used: Pol II (MABI0601,
MBL International), Ser2P (MABI0602, MBL Interna-
tional), Ser2P (5095, Abcam), Ser5P (MABI0603, MBL
International), Ser5P (5131, Abcam), LEO1 (A300–175A,
Bethyl Laboratories), CDC73 (A300–170A, Bethyl Lab-
oratories), SPT6 (15616S, Cell Signaling Technology),
CDK12 (11973S, Cell Signaling Technology), Cyclin K
G-11 (sc-376371, Santa Cruz Biotechnology), -tubulin
(6046, Abcam), nucleolin (ab22758, Abcam), and histone
H3 (ab1791,Abcam). Secondary antibodieswere purchased
from Merck Millipore (Goat Anti-Rabbit IgG Antibody,
HRP-conjugate, 12-348, and Goat Anti-Mouse IgG Anti-
body, HRP conjugate, 12-349), the chemiluminescent sub-
strate (SuperSignal West Pico PLUS) from Thermo Fisher,
and the membranes visualized on an iBright FL1000 Imag-
ing System (Thermo Fisher). Quantification of the western
blots was performed with Image Studio Lite software.
mNET-seq and library preparation
mNET-seq was carried out in biological duplicates as previ-
ously described (29) with minor changes. In brief, the chro-
matin fraction was isolated from 4 × 107 CDK12as cells
treated with DMSO and 1-NM-PP1. Chromatin was di-
gested in 100 l of MNase (40 units/l) reaction buffer for
2–3 min at 37◦C in a thermomixer (1400 rpm). After ad-
dition of 10 l EGTA (25mM) to inactivate MNase, sol-
uble digested chromatin was collected by 13 000 rpm cen-
trifuge for 5 min. The supernatant was diluted with 400
l of NET-2 buffer and antibody-conjugated beads were
added. Antibodies used: Pol II (MABI0601, MBL Inter-
national), Ser2P (MABI0602, MBL International), Ser2P
(5095, Abcam), and Ser5P (5131, Abcam). Immunoprecip-
itationwas performed at 4◦C for 1 h. The beadswerewashed
with 1 ml of NET-2 buffer six times with 100 l of 1xPNKT
(1xPNKbuffer and 0.05%TritonX-100) buffer once in cold
room. Washed beads were incubated in 200 l PNK reac-
tion mix in Thermomixer (1400 rpm) at 37◦C for 6 min.
After the reaction, beads were washed with 1 ml of NET-
2 buffer once and RNA was extracted with Trizol reagent.
RNA was suspended in urea Dye and resolved on 6% TBU
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Table 1. List of primers used in this study
Name Sequence of forward primer Sequence of reverse primer
NEG TGGTACAACCACAGCTCAGTG AAGCTGGACATGGTTGTGTG
KPNB1 TSS+0.2 TTACTTCCTCCCTCCAAATGGG ACAGCCTCCCTTCCTTCTTTC
KPNB1 TSS+3.2 GCCCAGAGAACAAGAAATCG GGAATGGACAAGCTGTGTTG
KPNB1 TSS+20.2 TGCAAGAGCCAGTGGGAACACTT CCTCTACTCAGCAATGATACTTC
KPNB1 pA-4.8 CTGAGGAAACTGAAGAACCAAG GAAGGCAGTGCTTGCCAGAAT
KPNB1 pA-2.9 GAGGAGTGTGCACGGATGCTGAA CCAAGATGGCCGATGTTATGG
KPNB1 pA-0.4 TAGTTACCGTCTGCTTGGGAAGATG CCTCTGACAGCAAGTCCAACATT
KPNB1 pA+1.4 GACTCATCACACCAAGGTCAC GATAGTGCTGGGAAGGAAATGG
KPNB1 pA+2.6 GTACATCTCAGCTTTGGCATATG GCCCAGAACATAGCAGGCATTGC
KPNB1 pA+4.1 GTTTCACCGTGTTAGCCAGGATGG CCACAGCCATGTTCATTTCTGC






35–100 nt RNAs, a gel fragment was cut between BPB and
XC dye markers. A 0.5 mlL tube was prepared with 3–4
small holes made with 25G needle and placed in a 1.5 ml
tube. Gel fragments were placed in the layered tube and
broken down by centrifugation at 12 000 rpm for 1 min.
The small RNAs were eluted from the gel using RNA elu-
tion buffer (1 M NaOAc and 1 mM EDTA) at 25◦C for
1 h in Thermomixer (900 rpm). Eluted RNA was purified
with SpinX column (Coster) with two glass filters (Milli-
pore) and the flow-through RNA was ethanol precipitated.
RNA libraries were prepared according to manual of NEB-
Next small RNA library prep kit (NEB). 12–14 cycles of
PCR were used to amplify the library. Deep sequencing
(Hiseq4000, Illumina) was conducted by the high through-
put genomics team of the Wellcome Trust Centre for Hu-
man Genetics (WTCHG), Oxford.
TT-seq and library preparation
TT-seq was performed as described (27,31), with minor
changes. Specifically, 6× 107 cells, grown in absence of peni-
cillin and streptomycin, from two biological replicates were
treated for 15 and 30 min with solvent (DMSO) or 7.5M
1-NM-PP1 (NM) at 37◦Cand 5%CO2. For the 15min treat-
ment, cells were exposed to 10 min 500 M of 4-thiouracil
(4sU, Carbosynth, NT06186) after 5 min of DMSO or NM
treatment (15 min total treatment). For the 30 min treat-
ment, cells were exposed to 10 min 500 M of 4-thiouracil
(4sU, Carbosynth, NT06186) after 20 min of DMSO or
NM treatment (30 min total treatment). Cells were lysed
in 5 ml of QIAzol (Qiagen) and 300 ng of RNA spike-
ins mix were added to each sample. RNA spike-ins were
produced as described (27). RNAs were sonicated to ob-
tain fragments of <10 kb using AFAmicro tubes in a S220
Focused-ultrasonicator (Covaris Inc, parameters: 10 s, peak
power 100, cycles 200, duty cycle 1%). 4sU-labeled RNAs
were purified from 240 g of each of the fragmented RNAs.
Biotinylation and purification of 4sU-labeled RNAs was
performed as described (27,32). 100 ng of input RNA was
used for strand-specific library preparation according to the
Ovation Universal RNA-seq System (NuGEN). Libraries
were prepared using random hexamer priming only.
QUANTIFICATION AND STATISTICAL ANALYSIS
TT-seq data preprocessing and global normalization param-
eters
Paired-end 75 base reads with additional 6 base reads of
barcodes were obtained for each of the samples. Reads were
demultiplexed and mapped using STAR 2.5.2b (33) to the
hg20/hg38 (GRCh38) genome assembly (Human Genome
Reference Consortium) with maximum 2%mismatches and
only unique alignments were retained. SAMtools was used
to quality filter SAM files, whereby alignments withMAPQ
smaller than 7 (-q 7) were skipped and only proper pairs (-
f2) were selected. Further data processing was carried out
using the R/Bioconductor environment. We used a spike-
in (RNAs) normalization strategy essentially as described
(27) to allow observation of global shifts (sequencing depth)
σ j , cross-contamination rate  j (proportion of unlabeled
reads purified in the TT-seq samples) and antisense bias ra-
tio c j (ratio of spurious reads originating from the oppo-
site strand introduced by the reverse transcription reaction).
Read counts (kij) for spike-ins were calculated using HTSeq
(34). Calculations for each parameter are described in the
following in more detail.
Antisense bias ratio c j
Antisense bias ratios were calculated for each sample j ac-
cording to






for all available spike-ins i.
Cross-contamination rate  j
The cross-contamination rate  j was calculated for each
sample j as
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Definition of transcription units based on the UCSC RefSeq
genome assembly GRCh38 (RefSeq-TUs)
For each annotated gene, transcription units were defined as
the union of all existing inherent transcript isoforms (UCSC
RefSeq GRCh38).
TT-seq processing with global normalization parameters
The number of transcribed bases (tbj) or read counts (kj) for
RefSeq-TUs were normalized and corrected for antisense
bias cj, sequencing depth σ j as follows using the parameters
calculated as described above. The cross-contamination rate
estimates for TT-seq in HEK293 were very low and were
thus not corrected for.
Antisense bias correction
The real number of read counts or coverage sij for tran-
scribed unit i in sample j was calculated as
si j = Si j − c j Ai j
1 − c2j
where Sij and Aij are the observed numbers of read counts
or coverage on the sense and antisense strand.
Read counts per kilobase (RPK)
RPKs were calculated upon antisense bias corrected read
counts (kj) falling into the region of a RefSeq-TU divided
by its length in kilobases.
TT-seq normalization
For a robust normalization, we first identified a sub-
group of RefSeq-TU’s as non-differentially expressed (non-
DE) for both time points over the response of NM-
PP1(CDK12as inhibitor) using DESeq2 package. Based on
the antisense bias corrected RPKs, a group of expressed
TUs [n = 5631] was defined to comprise all TUs with an
RPK of 100 or higher in two summarized replicates of TT-
seq 15 min samples without inhibitor treatment. An RPK
of 100 corresponds to approximately a coverage of 10 per
sample due to an average fragment size of 200. Within this
group, a subset of TUs having a length >50 kb [n = 1867]
was used to identify the non-DE TU’s.
The antisense bias corrected coverage sij of transcribed







where σ j was balanced between replicates via classical size
factor normalization to gain statistical power in the differ-
ential expression analysis.
On the resulting 140 non-DERefSeq-TUs, size factors for
each sample were then estimated as described by Equation
(5) in DESeq package (34) to correct for library size and
sequencing depth variations.
Visualization
For visualization, read coverages were summed up over
replicates, size factors for each condition were calculated
on the 140 non-DE RefSeq-TUs by Equation (5) in DE-
Seq package (34) and used to correct for library size and
sequencing depth variation.
For plotting, the expressed gene set is defined as follows:
Based on the antisense bias corrected RPKs, a group of ex-
pressed TUs [n = 11 282] was defined to comprise all TUs
with an RPK of 20 or higher in two summarized replicates
of TT-seq 15 min samples without inhibitor treatment. An
RPK of 20 corresponds to approximately a coverage of 2
per sample due to an average fragment size of 200.
Simulation of TT-seq data based on elongation velocity pro-
files
Based on the following model we simulated TT-seq cover-
age values by providing elongation velocity profiles v(t), a
labeling duration tlab and a uracil content dependent label-
ing bias
l f = 1 −
(
1 − plab)#u f
plab denotes the labeling probability (set to 0.01) and
#u f the number of uracil residues of a given fragment f (set
to 0.28 times fragment length). Elongating polymerases are
propagated at nucleotide resolution along the template in a
time-dependent manner. Each position of elongating poly-
merases τ ∗ can bemapped to its respective time of transcrip-





Consequently, the progression of a polymerase at any





v (t) dt −
t∗∫
0




while v(t) is the current velocity function at absolute time.
With this equation, the movement of single polymerases
over the course of labeling can be tracked. Start and end
positions of fragments can be derived given the positions
of any given polymerase at τ (t, t − tlab) for any given tran-
scription time. We used the number of uracil residues
present in the RNA fragment #u f to weight the amount
of coverage contributed by this fragment as l f . Addition-
ally, we applied a size selection similar to that in the orig-
inal protocol for fragments below 80 bp in length with a
sigmoidal curve that mimics a typical size selection spread.
This was done for templates resembling genes of sizes∼0,1-
2000 kbp. The resulting gene-wise RNA synthesis profiles
were subsequently accumulated to yield meta-gene profiles.
mNET-seq data processing
mNET-seq data were processed as follows: adapters
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the following parameters: -q 15, 10 –minimum-length
10 –A GATCGTCGGACTGTAGAACTCTGAAC –a
AGATCGGAAGAGCACACGTCTGAACTCCAGTC
AC. Trimmed reads were mapped to the human hg38
reference sequence with Tophat2 and the parameters –g 1
–r 3000 –no-coverage-search. SAMtools was used to retain
only properly paired and mapped reads (-f 3). A custom
python script (28) was used to obtain the 3′ nucleotide
of the second read and the strandedness of the first read.
Strand-specific bam files were generated with SAMtools.
FPKM normalized bigwig files were generated for each
bam files with Deeptools2 (35) bamCoverage tool (-bs 1 –p
max –normalizeUsing RPKM). For plotting, the expressed
gene set is defined as follows: Based on the antisense bias
corrected RPKs, a group of expressed TUs [n = 11282].
mNET-seq and ChIP-seq normalization
The total pol II mNET-seq treated with DMSO and NM
15 min were re-normalized to a set of 140 genes found to be
non-affected in the spiked-in TT-seq analysis after 15 and 30
min inhibition. The re-normalization factor was calculated
from the average fold change on total pol II signal between
DMSO and the NM conditions across the gene bodies of
this set of non-affected genes found in TT-seq. For the total
pol II mNET-seq metaprofiles and total pol II quantifica-
tion, the re-normalization factors for NM 15 min R1 and
R2 are 0.90 and 1.11, respectively. The Ser2P and Ser5P 15
min were normalized to the CTD phosphorylation signals
in histone genes (see Results and Supplementary Figure S4)
with the following normalization factors for the merged bi-
ological replicates: Ser2PMABI0602: 0.626, Ser2P ab5095:
0.544 and Ser5P ab5131: 0.791.
ChIP-seq data processing
Adapters were trimmed with Cutadapt in paired-end mode
with the same parameters as mNET-seq. Obtained se-
quences were mapped to the human hg38 reference genome
with Bowtie2. Properly paired and mapped reads were fil-
tered with SAMtools. PCR duplicates were removed with
Picard MarkDuplicates tool. FPKM normalized bigwig
files were generated for each bam files with Deeptools2
bamCoverage tool (-bs 10 –pmax –normalizeUsingRPKM
–e). For theHEK293ChIP-seq presented in Supplementary
Figure S2B, the pol II signal was normalized to the KPNB1
gene body (TSS + 500 bp to poly(A) site, NM normaliza-
tion factor: 0.494) as this gene was found to be non-affected
by pol II ChIP-qPCR. CDK12as pol II ChIP-seq NM nor-
malization factors are 1.345 and 0.840 for replicates 1 and
2, respectively. Ser2P NM normalization factors are 1 and
1.429 for replicates 1 and 2, respectively. Ser5P NM nor-
malization factors are 1.275 and 1.269 for replicates 1 and
2, respectively.
Metagene profiles
Metagene profiles of genes scaled to the same length were
then generated with Deeptools2 computeMatrix tool with
a bin size of 10 bp and the plotting data obtained with plot-
Profile –outFileNameData tool. Graphs representing the
(IP – Input) signal (ChIP-seq) or the mNET-seq signal were
then created with GraphPad Prism 8.4.0. Metagene profiles
are shown as the average of two biological replicates.
P-values and significance tests
P-values were computed with an unpaired two-tailed Stu-
dent’s t test. Statistical tests were performed in GraphPad
Prism 8.4.0.
RESULTS
Rapid and specific CDK12as inhibition in human cells
Several studies using RNAi-mediated knockdown of
CDK12 have highlighted roles for this kinase in CTD phos-
phorylation and expression of DDR genes (3,4,17). To
assess whether these effects are mediated by CDK12 ki-
nase activity, the loss of CDK12 itself, or indirect effects
due to the long time-frame of knockdown, we produced a
CDK12as HEK293 cell line, using CRISPR/Cas9, where
the gatekeeper phenylalanine residue (codon TTT) is mu-
tated to glycine (codonGGT) (Supplementary Figure S1A).
This allows rapid and selective inhibition of CDK12 ki-
nase activity with a bulky ATP-analog 1-NM-PP1 (NM)
(14,16,36), without affecting levels of the protein itself,
which has been shown to interact with other components
of the transcription/RNAprocessingmachinery (12,19,37).
Importantly, the growth rate of the CDK12as cells is not
lower than that of the parental HEK293 cell line (Sup-
plementary Figure S1B). Also, CDK12 and Cyclin K pro-
tein levels are unchanged in CDK12as cells compared to
the parental cell line, as measured by western blot analyses
(Supplementary Figure S1C and D).
To determine which concentration of NM to use, we fol-
lowed the growth of CDK12as and the parental HEK293
cells after the addition of 5, 7.5 and 10 M of NM to the
medium using either an alamarBlue HS cell viability assay
or continuous label-free monitoring by xCelligence (Sup-
plementary Figure S1E and F). In both cases, 7.5 MNM
affects the viability and growth of CDK12as cells with less
effect on HEK293, whereas 10 M NM affects both cell
lines. This is in agreement with previously published data on
CDK12as inhibition in HeLa cells (14). Importantly, short-
term treatment of HEK293 and CDK12as cells with 7.5M
NM does not affect the protein levels of CDK12 and Cy-
clin K (Supplementary Figure S1G and H) and takes many
hours to affect cell viability (Supplementary Figure S1E).
We have therefore treated cells with this inhibitor concen-
tration for 15 or 30 min, in order to determine the immedi-
ate effect of CDK12 inhibition. Importantly, pol II distri-
bution on expressed transcription units in the parental cells
is not affected by short-termNM treatment as measured by
pol II chromatin immunoprecipitation followed by quanti-
tative PCR (ChIP-qPCR) of KPNB1 and ChIP-sequencing
(ChIP-seq) (Supplementary Figure S2A and B).
CDK12as inhibition globally decreases RNA synthesis
To monitor changes in RNA synthesis upon CDK12as in-
hibition, we performed TT-seq with RNA spike-ins after
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Figure 1. CDK12as inhibition globally decreases RNA synthesis. (A) Experimental design. (B) Metagene analysis of TT-seq signal for expressed genes
after treatment of cells with DMSO (black) versus 7.5 MNM treatment (blue) for 15 min (left) or 30 min (right). The TT-seq coverage was averaged and
aligned at their transcription start sites (TSSs) and polyadenylation (pA)-sites. Shaded areas around the average signal (solid lines) indicate confidential
intervals. (C) Box plots of different length classes show the ratio of transcribed bases after 15 min (left) and 30 min (right) inhibition of CDK12as compared
to control. (D) Metagene analysis for different length classes comparing the average TT-seq signal before (DMSO treatment, black) and after CDK12as
inhibition (7.5 M NM treatment, blue) for 15 min (upper panel) and 30 min (lower panel). The TT-seq coverage was averaged and aligned at their
transcription start sites (TSSs) and polyadenylation (pA)-sites. Shaded areas around the average signal (solid lines) indicate confidential intervals. (E)
Schematic representation of TT-seq signal changes along the gene body upon elongation velocity change. Upper panel: steady state transcription. Lower
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this analysis, treatment with NM has little effect on tran-
scription in the parental cells (Supplementary Figure S2C
and D). However, metagene profiles of TT-seq signals av-
eraged over expressed genes (see Materials and Methods)
in CDK12as cells show a decreased TT-seq signal across
gene bodies after 15 min of inhibition, indicating reduced
RNA synthesis, either as the result of reduced elongation or
loss of polymerase, in 11 182 transcription units, including
10,393 protein-coding genes and 789 unclassified transcrip-
tion units (Figure 1B–D). CDK12as inhibition for 30 min
instead leads to a recovery of RNA synthesis activity at the
beginning of genes (Figure 1C, right, D lower panel).
Recovery of the TT-seq signal after 30 min could be ex-
plained by a higher density of slower polymerases spreading
from the transcription start site and gradually populating
the gene body (Figure 1E). This effect would not require any
changes in initiation frequencies, but could stem only from
an increase in polymerase density over genes due to slower
elongation. After CDK12as inhibition, polymerases dra-
matically slow down, resulting in a lower amount of RNA
synthesis, which may be successively restored by a higher
number of polymerases occupying the gene body provided
the same number of initiation events. This model predicts
that recovery of RNA synthesis takes longer for long genes
and shorter for short genes (Figure 1C–E). As human genes
take on average longer than 30min to be transcribed, recov-
ery of RNA synthesis and TT-seq signal would be limited to
the 5′-region of genes and not observed for many 3′-regions,
leading to the observed slope in the TT-seqmetagene profile
(Figure 1C–E).
To test this model further, we simulated TT-seq metagene
profiles based on a kinetic model that computes RNA syn-
thesis at each gene position based on initiation rates and
elongation velocities. The model readily recapitulates the
observed TT-seq profiles if we assume that CDK12 inhibi-
tion induces rapid and global downregulation ofRNAelon-
gation without affecting transcription initiation frequency
(Supplementary Figure S2E and F). Thus, TT-seq analysis
and kinetic modeling supports the notion that CDK12 is re-
quired for normal transcription elongation, and the elonga-
tion defect resulting from its inactivation is readily observed
after rapid inhibition followed by immediate monitoring of
RNA synthesis.
Inhibition of CDK12as affects transcription elongation
To confirm that the observed decrease in RNA synthe-
sis activity results from reduced elongation, we performed
mNET-seq of total pol II in CDK12as cells after 15 min
of NM treatment (Figure 2A). mNET-seq identifies the
last nucleotide transcribed by sequencing the RNA present
in the active site of immunoprecipitated pol II (29). The
mNET-seq data were normalized to a set of genes found to
be unaffected in TT-seq (see Materials and Methods). In-
hibition of CDK12as results in an increase of pol II signal
in the gene body of the vast majority of expressed pol II-
transcribed genes within 15 min of inhibition (Figure 2B
and C), consistent with higher densities of more slowly-
elongating pol II. ChIP-seq of pol II gives a similar picture
after 15 min inhibition of CDK12as (Supplementary Fig-
ure S3A). We have confirmed this increase of pol II occu-
pancy in the gene body of a model gene, KPNB1, by per-
forming pol II ChIP-qPCR after 15 and 30 min treatment
of CDK12as cells with NM (Supplementary Figure S3B).
The higher pol II signal results from an increased pol II res-
idence time in gene bodies due to slower elongation, and not
from an increased amount of pol II entering elongation, as
shown by the decrease in RNA synthesis in TT-seq (Figure
1).
Further analysis shows that transcription of pol II-
transcribed genes of all lengths is affected by CDK12as in-
hibition, with a wave of elongation-compromised pol II
reaching the ends of the shortest genes first (Figure 2D).
Genes <9 kb have a less pronounced elongation defect af-
ter CDK12as inhibition than genes >9 kb as measured by
both TT-seq and mNET-seq (Figures 1D and 2D). In ad-
dition, the elongation defect increases with increasing dis-
tance from the TSS for all gene length classes (Figure 1D).
This is more apparent after analysis of TT-seq and mNET-
seq data for the first few kilobases of genes>6.5 kb (Supple-
mentary Figure S3C and D). Thus, the effect of CDK12as
inhibition starts early in the transcription cycle and in-
creases with increasing distance from the TSS (Supplemen-
tary Figure S3C andD).Many of the genes<9 kbwill there-
fore be too small to exhibit a major effect of CDK12as in-
hibition on elongation as pol II will reach the end of genes
soon after the elongation defect starts to occur.
Interestingly, on genes longer than 21.1 kb, pol II in-
creases in the gene body but is specifically reduced down-
stream of the poly(A) site (Figure 2D), before the wave of
slower polymerases reaches this region. Single gene exam-
ples of this phenomenon are shown in Supplementary Fig-
ure S3E and this can also be observed by pol II ChIP-qPCR
of the KPNB1 gene (Supplementary Figure S3B).
Since transcription of intron-containing protein-coding
genes is affected by short-term inhibition of CDK12as, we
investigated whether transcription of intronless (n = 5396),
histone (n = 118), and snRNAs (n = 36) genes is also al-
tered (Supplementary Figure S4A and B). TT-seq signals
for intronless and pol II-transcribed snRNA genes decrease
after 15 or 30 min inhibition, whereas mNET-seq signals
on intronless genes are not markedly affected and slightly
reduced on snRNA genes. We interpret this to mean that
pol II is slower on these genes but pol II is not building
up as they are relatively short (the intronless and snRNAs
have an average size of 948 and 150 bp, respectively). TT-
seq signals for histone genes instead are either unaffected
or slightly increased and mNET-seq signals unaffected by
CDK12as inhibition. We therefore conclude that transcrip-
tion of histone genes does not require CDK12 activity. We
have confirmed this by pol II ChIP-qPCR for five different
histone genes (Supplementary Figure S4C).
The primary effects of CDK12as inhibition on transcrip-
tion of intron-containing protein-coding genes are therefore
an elongation defect in gene bodies and loss of pol II down-
stream of the poly(A) site. Taken together, the results indi-
cate that CDK12 plays a role in maintaining efficient tran-
scription elongation velocity and processivity on these hu-
man genes. Efficient transcription of intronless genes and
snRNA genes also appears to require CDK12, although the
defects are less apparent. Histone genes, on the other hand,
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Figure 2. Inhibition of CDK12as affects transcription elongation. (A) Experimental design.mNET-seq using an antibody against total pol II was performed
in CDK12as HEK293 cells after treatment with 15 min of DMSO solvent control or 7.5 MNM. (B) Metagene analysis comparing the average mNET-seq
signal before and after CDK12as inhibition for 15 min of expressed genes. (C) Violin plots of the different length classes noted show the ratio of mNET-
seq signal after 15 min inhibition of CDK12as compared to control. (D) Metagene analysis for the different length classes noted comparing the average
mNET-seq signal before and after CDK12as inhibition for 15 min. The mNET-seq reads were averaged and aligned at their TSSs and (pA)-sites.
CDK12 phosphorylates transcribing pol II
mNET-seq can also be carried out with CTD phospho-
site-specific antibodies to detect nascent RNA associated
with particular pol II phospho-isoforms (29). Accordingly,
we have used mNET-seq to investigate the primary ef-
fect of CDK12as inhibition on CTD phosphorylation. As
short-term inhibition of CDK12as is sufficient to cause
global changes in transcription (Figures 1 and 2), we treated
CDK12as with NM for 15 min and obtained mNET-seq
profiles for pol II CTD phosphorylation at Ser2P and Ser5P
using antibodies against each of these phospho-forms (Fig-
ure 3).
As transcription of histone genes is relatively unaffected
by CDK12as inhibition, we have investigated whether pol
II CTD Ser2P and Ser5P levels are affected by CDK12as
inhibition. Ser2P and Ser5P ChIP-qPCR for five different
histone genes indicates that Ser2P and Ser5P, ratioed and
unratioed to pol II levels, is unaffected by NM treatment
(Supplementary Figure S4C), indicating no requirement for
CDK12 for CTD phosphorylation during transcription of
these genes. Interestingly, the level of Ser2P relative to pol II
on histone is generally much lower than on other protein-
coding genes (a ratio of up to 0.6 on histone genes and a
ratio of >40 at the end of KPNB1 with ab5095) (Supple-
mentary Figures S4 and S5), which is consistent with the
relative lack of requirement for a Ser2 kinase.We have there-
fore used the levels of Ser2P and Ser5P on histone genes to
normalize our mNET-seq Ser2P and Ser5P data (see Mate-
rials and Methods). We have displayed the results with and
without normalisation of the mNET-seq signals to total pol
II levels to take changes of pol II occupancy into account
(Figure 3A and B). Figure 3C shows the genome browser
track of the unratioed mNET-seq results for the CCND2
gene, a ∼32 kb long gene displaying increased pol II sig-
nal in the gene body and a loss of pol II downstream of the
poly(A) site. The mNET-seq signals for two different Ser2P
antibodies and for the Ser5P antibody show a decrease af-
ter CDK12as inhibition when ratioed to the total pol II level
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Figure 3. CDK12 phosphorylates transcribing pol II. (A) Meta-analyses of scaled expressed genes of mNET-seq for Ser2P with and without normalization
to pol II after treatment of CDK12as cells withDMSO (black) or 7.5MNM(orange) for 15min. (B)Meta-analyses of scaled expressed genes ofmNET-seq
for Ser5P with and without normalization to pol II after treatment of CDK12as cells with DMSO (black) or 7.5 MNM (red) for 15 min. (C) mNET-seq
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Figure 4. ChIP-seq analysis of CDK12 phosphorylation of transcribing pol II. (A) Meta-analyses of scaled expressed genes of ChIP-seq for Ser2P (ab5095)
with and without normalization to pol II after treatment of CDK12as cells with DMSO (black) or 7.5MNM (orange) for 15 min. (B) Meta-analyses of
scaled expressed genes of ChIP-seq for Ser5P (ab5131) with and without normalization to pol II after treatment of CDK12as cells with DMSO (black) or
7.5 MNM (red) for 15 min.
on Ser2P and Ser5P phosphorylation is seen using ChIP-
seq of Ser2P and Ser5P and ChIP-qPCR on KPNB1 (Fig-
ure 4A, B, Supplementary Figure S5A and B) Interestingly,
we observed a loss of Ser5P phosphorylation at the TSS
of genes after CDK12as inhibition, indicating that CDK12
acts as a Ser5 kinase at this step and could affect mRNA
capping, which relies on Ser5P (38) (Supplementary Figure
S5B). We first confirmed the loss of Ser5P by ChIP-qPCR
on the TSS ofKPNB1 andCCND2 after 15- and 30-min in-
hibition of CDK12as (Supplementary Figure S5C and D).
To investigate a possible effect on mRNA capping, we per-
formedChIP-qPCRofRNGTT, the enzyme responsible for
the first two catalytic steps of the cap formation, and found
a decrease in signal at the TSS following CDK12as inhibi-
tion consistent with the reduction in Ser5P relative to total
pol II (Supplementary Figure S5C and D).
We also carried out western blot analyses on chromatin-
associated pol II with antibodies against different pol II
CTD phospho-isoforms after treating cells with NM for 15
and 30min (Supplementary Figure S6A and B). In line with
the results of mNET-seq analysis (Figure 3A and B), inhi-
bition of CDK12as markedly affects Ser2 and Ser5 phos-
phorylation within 15 min, as measured with two different
antibodies against thesemodifications (Supplementary Fig-
ure S6A and B). Both Ser2P and Ser5P continue to be af-
fected after 30 min, with a further decrease in phosphoryla-
tion observed for Ser2P MABI0602 and Ser5P MABI0603
(Supplementary Figure S6A and B). In contrast, no loss
of Ser2P or Ser5P occurs when HEK293 cells are treated
with NM for 15 or 30 min (Supplementary Figure S6C and
D). Loss of Ser2P and Ser5P after 15 min of inhibition of
CDK12as was also confirmed by performing immunopre-
cipitation of total pol II followed by western blotting with a
Ser2P (ab5095) and Ser5P (ab5131) antibody (Supplemen-
tary Figure S6E). These results are consistent with previous
in vitro kinase assays and analysis of CDK12as HeLa cells
(14,15). Taken together, the western and mNET-seq analy-
ses indicate that CDK12 contributes to phosphorylation of
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CDK12 activity is required for stable association of elonga-
tion and termination factors with chromatin
Our results indicate that CDK12 is required for normal
transcription elongation of most pol II-transcribed genes
(Figures 1 and 2). However, the mechanism remains un-
clear. CDK12 activity may be required for the recruitment
of elongation factors to transcribing pol II or for the sta-
bilization of their interactions with pol II. We have there-
fore tested by ChIP-seq and ChIP-qPCR whether the lev-
els of the LEO1 and CDC73 subunits of the elongation
factor PAF1 complex (PAF1C) and the elongation factor
SPT6 detected in chromatin are affected by CDK12as inhi-
bition (Figure 5A–C and S7). We have displayed the LEO1
and SPT6 ChIP-seq results with or without normalisation
to pol II, to take the changes in pol II levels into account
(Figure 5A and B). The level of LEO1 and SPT6 associated
with expressed genes appears to be affected genome-wide.
In addition, LEO1 appears to be selectively lost from the
newly-elongating pol II as long genes (e.g. >41.3 kb) have
a reduction in the ratio of LEO1 to total pol II at the 5′
end, but not at the 3′ end, where the pol II that initiated be-
fore treatment is still elongating (Figure 5C). In contrast,
SPT6 is reduced more globally as a decrease in signal is
also observed at the 3′end of long genes, albeit less than
at the 5′ end of genes (Figure 5D). In addition, the asso-
ciation of CDC73 and SPT6 by ChIP-qPCR with KPNB1,
with or without normalisation to pol II, is reduced after 15
min inhibition of CDK12as (Supplementary Figure S7C).
Similarly to LEO1, the level of CDC73 on KPNB1, which
is ∼34 kb long, is decreased in the gene body but not at
the 3′ end by CDK12as inhibition. Western analyses also
indicate that inhibition of CDK12as decreases the associ-
ation of SPT6, LEO1, and CDC73 with chromatin (Fig-
ure 5E and F). The loss of SPT6, LEO1, and CDC73 from
chromatin is mirrored by an increase in the level of these
proteins in nucleoplasm fraction after CDK12as inhibition,
with a particularly marked increase in nucleoplasmic SPT6
(Supplementary Figure S8A and B). These results are in
line with a loss of association of these factors with chro-
matin, although we cannot rule out that changes in post-
translation modifications are affecting antibody reactivity.
Importantly, no loss of these factors from chromatin is ob-
served when HEK293 cells are treated with NM (Supple-
mentary Figure S8C–F). Also, the decrease on chromatin
of SPT6, LEO1, and CDC73 is not due to protein degrada-
tion, as the global protein level of these elongation factors
remains stable after NM treatment, both in HEK293 and
CDK12as cells (Supplementary Figure S8G and H). The re-
sults of immunoprecipitation of total pol II from cell ex-
tracts followed by western analyses of total pol II and SPT6
after 15 min inhibition of CDK12as also suggest that SPT6
association with pol II is reduced (Supplementary Figure
S9). Taken together, these results support the notion that
CDK12 activity plays a key role in ensuring that the critical
elongation factors PAF1C and SPT6 are part of the pol II
elongation complex (19,39,40). Loss of these factors could
readily explain the elongation defect that we observe after
CDK12 inhibition.
It was previously shown that CDK12 is required for the
recruitment of polyadenylation/transcription termination
factors (17,18). To investigate further whether the loss of
Ser2P and PAF1C following CDK12as inhibition affects
the recruitment of termination factors, we performed ChIP-
seq of CPSF73, the enzyme responsible for the cleavage
of the pre-mRNA at the poly(A) site (Supplementary Fig-
ure S10). We observed a general loss of CPSF73 levels af-
ter 15 min of CDK12as inhibition (Supplementary Figure
S10A). Importantly, the level of CPSF73 is unaffected at
the 3′end of long genes (> 41.3 kb), suggesting that, simi-
larly to LEO1 and CDC73, CPSF73 is lost from the newly-
elongating pol II (Supplementary Figure S10B). We con-
firmed the drop in CPSF73 levels detected at the same point
as newly-initiated pol II after CDK12as inhibition by ChIP-
qPCR on the KPNB1 gene (Supplementary Figure S10C).
These results are in agreement with the finding that Ser2P
is retained relative to pol II at the 3′ end of long genes
(Supplementary Figure S11). In contrast Ser5P is reduced
relative to pol II at the end of long genes (Supplementary
Figure S11).
DISCUSSION
Here, we have established a protocol to rapidly and specifi-
cally inhibit CDK12 in human cells and immediately mon-
itor changes in RNA synthesis and the occupancy of en-
gaged pol II genome-wide. We have restricted our analysis
to the first 30 min after inhibition to capture the primary
effect of loss of CDK12 kinase activity. An additional ben-
efit of our strategy is the potential to lose the activity of
the kinase independently of losing the protein itself. In con-
trast to previous studies, our results indicate that CDK12
activity is required for efficient elongation of transcription
of the vast majority of expressed pol II-dependent genes, in-
dicating that it is a general transcription kinase, rather than
playing a specific role in transcription of genes longer than
45 kb (25). Our results further suggest that CDK12 plays
an increasing role in elongation after pol II has passed the
CDK9-regulated early-elongation checkpoint (EEC) and
entered productive elongation (Supplementary Figure S3C
and D) (41). It has been shown that the pol II elongation
rate increases during transcription (42) and CDK12 may
therefore play a key role in pol II speeding up as it trav-
els away from the EEC, explaining the increase in the elon-
gation defect as pol II moves further from the TSS. Ex-
pression of long genes will therefore be disproportionately
affected by an elongation defect and this will be ampli-
fied over time. This would therefore explain why CDK12
knockdown experiments show a loss of expression of long
genes, in particular DDR genes. In addition, as CDK12
makes important contacts with RNA processing and elon-
gation factors (12,18,19), the long-term loss of the protein
itself may contribute to the gene-type-specific defects in
the level of mRNA from long DDR genes. A recent study
with CDK12as HCT116 cells also indicates that CDK12 ki-
nase activity is specifically required for transcription of long
DDR genes (13). However, in this case, pol II ChIP-seq was
performed after 4.5 h inhibition, which will result in a bias
in the analysis towards detection of a defect on long genes.
The effect of CDK12as inhibition on elongation of tran-
scription is readily explained by the loss of association
of LEO1 and CDC73, which are key components of the
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Figure 5. CDK12 activity is required for stable association of elongation factors with chromatin. (A) Meta-analysis of LEO1 subunit of the PAF1 complex
(PAF1C) ChIP-seq across scaled expressed genes. (B) Meta-analysis of SPT6 ChIP-seq across scaled expressed genes. (C) Meta-analyses of LEO1 ChIP-seq
ratioed to the total pol II signal before and after CDK12as inhibition for 15 min across scaled expressed genes for the different length classes noted. (D)
Meta-analyses of SPT6 ChIP-seq ratioed to the total pol II signal before and after CDK12as inhibition for 15 min across scaled expressed genes for the
different length classes noted. (E) Western blots of CDK12as cell chromatin extracts. Cells are either treated with 7.5 M 1-NM-PP1 or DMSO for 15 and
30 min as noted. The antibodies used are indicated on the right. Histone H3 was used as a loading control. (F) Quantitation of chromatin protein levels
of SPT6, LEO1, CDC73, and histone H3 in CDK12as cells relative to DMSO controls. Error bars = s.e.m. (n = 3 biological replicates). Statistical test:
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Figure 6. Model of CDK12 function in transcription. During the transcription cycle, CDK12 phosphorylates Ser2 and Ser5 of the pol II CTD and possibly
other factors involved in transcription such as SPT6. Inhibition of CDK12 affects the pol II elongation rate by affecting the recruitment and/or stability on
the chromatin of LEO1 and CDC73 from the PAF1 complex (PAF1C) and SPT6. CDK12 inhibition does not affect pol II pause release, which is mediated
by CDK9. Orange line with ‘cap’: capped mRNA; orange and red dot: Ser2P and Ser5P, respectively. Red and violet arrows: phosphorylation mediated
by CDK9 and CDK12, respectively.
SPT6. We cannot rule out that CDK12as inhibition causes
rapid nuclear export of these factors or that their associa-
tion with chromatin appears reduced due to epitope mask-
ing caused by changes in post-translational modifications.
However, CDK12as inhibition not only causes a decrease
in the level of elongation factors on chromatin but an in-
creased level in the nucleoplasm as would be expected if
CDK12 activity is required for their effective recruitment
to and/or stable association with pol II. CDK12 has al-
ready been shown to interact with the PAF1 complex (19).
It has also recently been shown that the CDK12/CDK13
inhibitor, THZ531, affects phosphorylation of SPT6 (25).
Phosphorylation of SPT6 by CDK12 could therefore play
a role in contacts between SPT6 and other components of
the elongation complex, including pol II and PAF1C (40).
In turn, loss of SPT6 association may further destabilize
the elongation complex (43). We therefore favour the no-
tion that CDK12 inhibition causes reduced association of
elongation factors with pol II through the loss of phospho-
rylation of one or more of its targets. Both loss of CDK12
and inhibition of CDK12 and CDK13 by THZ531 lead to
the activation of gene-internal poly(A) sites and premature
termination of transcription (10,25), which may be the di-
rect result of slower elongation as suggested (25) (Figure 6).
We also observed a loss of the polyadenylation factor
CPSF73 from newly-elongating pol II (Supplementary Fig-
ure S10). It was previously shown that CDC73 can inter-
act with CPSF73 (44) and our data support this observa-
tion as both PAF1C and CPSF73 are lost from the newly-
elongating pol II. CTD Ser2P also plays a role in CPSF73
recruitment (17). At the 3′ end of long genes, the retention
of CDC73 and Ser2Pwould therefore be sufficient to recruit
CPSF73 to/stabilize its interaction with the pol II elonga-
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is somewhat lost from the 3′ end of long genes, this mark is
likely to be less important for PAF1C/CPSF recruitment at
this point.
Notably, the effect of inhibiting CDK12 differs markedly
from the effect of CDK9 inhibition, which causes a drastic
loss of elongating pol II downstream of the early-elongation
checkpoint (EEC) (31,45). CDK9 and CDK12 therefore
play non-redundant roles in ensuring efficient transcrip-
tion of pol II-dependent genes. However, these two kinases
are intimately connected as CDK9 activity is required for
PAF1C recruitment and PAF1C in turn recruits CDK12
(1,19). In addition, inhibition of both CDK12 and CDK9
causes premature termination close to poly(A) sites where
Ser2P is peaking (45,46), indicating that the activity of both
kinases is required for the correct transition between elon-
gation and termination, through their phosphorylation of
Ser2 or other targets.
CDK12 knockdown and THZ531 inhibition studies in-
dicate that CDK12 phosphorylates Ser2 of the human pol
II CTD (3,4,7), whereas in vitro CDK12 has robust Ser5 ki-
nase activity (15,16). We find that detectable losses of Ser2P
and Ser5P occur rapidly after CDK12as inhibition, with the
biggest effect on Ser5P. Relevant to this, specific inhibition
of CDK12as in HeLa cells results in a decrease in detection
of pol II by both the H14 and H5 antibodies, which recog-
nize Ser5P and Ser2P, respectively (14,47,48). A recent study
with a CDK12as HCT116 cell line observed a decrease in
Ser5P but not of Ser2P following CDK12 inhibition (13).
We have shown here that association of a Ser5P-binding
capping factor with genes is affected by CDK12as inhibi-
tion. Our results therefore support the notion that CDK12
is amajor Ser5 kinase. However, based on previous findings,
we would have expected inhibition of CDK12as to cause a
greater loss of Ser2P. Thus, in at least some human cells, the
Ser2 kinase activity of CDK12may be somewhat redundant
with other Ser2 kinases, such as CDK9.
In conclusion, we have shown that inhibition of CDK12
causes a genome-wide pol II defect in pol II velocity and
processivity and loss of PAF1C components and SPT6 from
the newly-elongating pol II. Our findings also indicate that
CDK12 is both a CTD Ser2 and Ser5 kinase in vivo. It re-
mains to be determined whether CDK12 function in tran-
scription elongation is mediated through pol II CTD phos-
phorylation and/or through phosphorylation of other tar-
gets such as SPT6.
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